Author/Authors :
Kato, Junji Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Nakamura, Hajime Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Takada, Kohichi Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Murase, Kazuyuki Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Sakamoto, Hiroki Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Hayasaka, Naotaka Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Ishikawa, Kazuma Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Ikeda, Yuki Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Yoshida, Makoto Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Miyanishi, Koji Department of Medical Oncology - Sapporo Medical University School of Medicine, Japan , Iyama, Satoshi Department of Hematology - Sapporo Medical University School of Medicine, Japan , Kobune, Masayoshi Department of Hematology - Sapporo Medical University School of Medicine, Japan , Kobayashi, Ko Department of Urology - Sapporo Medical University School of Medicine, Japan , Shindo, Tetsuya Department of Urology - Sapporo Medical University School of Medicine, Japan , Masumori, Naoya Department of Urology - Sapporo Medical University School of Medicine, Japan , Sugita, Shintaro Department of Surgical Pathology - Sapporo Medical University School of Medicine, Japan
Abstract :
Papillary thyroid cancer (PTC) is considered an indolent cancer, but some PTC patients do present with distant metastases andtreatment strategies for such patients are not well established. Recently, lenvatinib, an inhibitor of multiple tyrosine kinases, hasbeen introduced to treat patients with advanced PTC but carries a risk of serious adverse events such as hemorrhage. Here, wereport a PTC patient with a left adrenal metastasis and lenvatinib-induced hemorrhage who underwent successful surgicalresection and was subsequently treated with a lower dose of lenvatinib. The patient has now been in a stable state with noadverse events for nearly two years. This case highlights the importance of surgical resection of metastatic PTC and subsequentlenvatinib therapy, even when the tumor is at an advanced stage.
Keywords :
Successful Treatment , Surgery , Lenvatinib , Patient , Adrenal Metastasis , Papillary Thyroid Cancer , Papillary thyroid cancer (PTC)
